Novo Nordisk is partnering with Septerna in a $2B+ deal to develop oral small molecules for obesity and diabetes, focusing on ...

Omada, the virtual chronic care provider, joins virtual physical therapy company Hinge Health in testing the public market’s ...

An order from a federal appeals court has kicked the battle wide open again over who holds the key patents for CRISPR-Cas9, a ...

The Trump administration laid out for the first time how Part B drugs could be selected for Medicare drug price negotiations ...

Cytokinetics's aficamten outperforms metoprolol in Phase 3 heart disease trial, but FDA approval delayed to December due to ...

A handful of generic and biosimilar manufacturers have said they feel prepared to ride out President Donald Trump’s potential ...

GSK said it is axing development of belrestotug and concluding its iTeos collaboration, which began with $625 million upfront ...

Andrew Witty is out as CEO of UnitedHealth Group after a tumultuous couple of years that included the shooting death of a top ...

White House drug pricing plan faces skepticism as experts question feasibility of Trump's executive order to align US prices ...

Plus, news about Neumora, Erasca, FibroGen, Tilt Biotherapeutics, Sangamo, Leap Therapeutics, Remedy Plan, Lexeo, Karyopharm, Tango Therapeutics and Humacyte.

Bayer cuts 2,000 jobs in Q1 2025, reaching 11,000 total layoffs amid reorganization. CEO Bill Anderson reports strong pharma ...

Azafaros raises $146M Series B to advance nizubaglustat into Phase 3 trials for rare lysosomal storage disorders, with ...